Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.
Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, Smith N, Villa S, Dransfield J, Clipson A, White D, Nessa K, Ferdous S, Howell M, Gupta A, Kilerci B, Mohan S, Frese K, Gulati S, Miller C, Jordan A, Eaton H, Hickson N, O'Brien C, Graham D, Kelly C, Aruketty S, Metcalf R, Chiramel J, Tinsley N, Vickers AJ, Kurup R, Frost H, Stevenson J, Southam S, Landers D, Wallace A, Marais R, Hughes AM, Brady G, Dive C, Krebs MG. Rothwell DG, et al. Among authors: krebs mg. Nat Med. 2019 May;25(5):738-743. doi: 10.1038/s41591-019-0380-z. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011204 Free article.
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients.
Jittla P, Graham DM, Zhou C, Halliwell J, O'Reilly S, Aruketty S, Azizi A, Germetaki T, Lowe J, Little M, Punnett G, McMahon P, Benson L, Carter L, Krebs MG, Thistlethwaite FC, Darlington E, Yorke J, Cook N. Jittla P, et al. Among authors: krebs mg. ESMO Open. 2022 Oct;7(5):100550. doi: 10.1016/j.esmoop.2022.100550. Epub 2022 Aug 19. ESMO Open. 2022. PMID: 35994790 Free PMC article.
Social determinants of health inequalities in early phase clinical trials in Northern England.
Rae S, Shaya S, Taylor E, Hoben J, Oluwashegun D, Lowe H, Haris N, Bashir S, Oing C, Krebs MG, Thistlethwaite FC, Carter L, Cook N, Greystoke A, Graham DM, Plummer R. Rae S, et al. Among authors: krebs mg. Br J Cancer. 2024 Sep;131(4):685-691. doi: 10.1038/s41416-024-02765-w. Epub 2024 Jun 24. Br J Cancer. 2024. PMID: 38914804 Free PMC article.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: krebs mg. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
98 results